GLUCOSE Renaudin

Information principale

  • Nom commercial:
  • GLUCOSE Renaudin 30 POUR CENT (3 g/10 ml), solution injectable en ampoule
  • Dosage:
  • 3 g
  • forme pharmaceutique:
  • solution
  • Composition:
  • composition pour une ampoule > glucose anhydre : 3 g . Sous forme de : glucose monohydraté 3,3 g
  • Mode d'administration:
  • intraveineuse
  • Unités en paquet:
  • 5 ampoule(s) 2 pointes en verre de 10 ml
  • Utiliser pour:
  • Humains
  • Type medicin:
  • médicament allopathique

Documents

Localisation

  • Disponible en:
  • GLUCOSE Renaudin 30 POUR CENT (3 g/10 ml), solution injectable en ampoule
    France
  • Langue:
  • français

Information thérapeutique

  • Domaine thérapeutique:
  • PRODUIT D'APPORT GLUCIDIQUE.
  • Descriptif du produit:
  • 559 321-7 ou 4009 559 321 7 8 - 5 ampoule(s) 2 pointes en verre de 10 ml - Déclaration de commercialisation non communiquée:;567 201-7 ou 4009 567 201 7 0 - 50 ampoule(s) bouteille en verre de 10 ml - Déclaration de commercialisation non communiquée:;567 202-3 ou 4009 567 202 3 1 - 100 ampoule(s) bouteille en verre de 10 ml - Déclaration de commercialisation:03/04/2006;559 322-3 ou 4009 559 322 3 9 - 10 ampoule(s) 2 pointes en verre de 10 ml - Déclaration de commercialisation non communiquée:;559 324-6 ou 4009 559 324 6 8 - 20 ampoule(s) 2 pointes en verre de 10 ml - Déclaration de commercialisation non communiquée:;559 325-2 ou 4009 559 325 2 9 - 30 ampoule(s) 2 pointes en verre de 10 ml - Déclaration de commercialisation non communiquée:;559 326-9 ou 4009 559 326 9 7 - 50 ampoule(s) 2 pointes en verre de 10 ml - Déclaration de commercialisation non communiquée:;559 327-5 ou 4009 559 327 5 8 - 100 ampoule(s) 2 pointes en verre de 10 ml - Déclaration de commercialisation:19/02/1997;372 130-3 ou 4009 372 130 3 5 - 5 ampoule(s) bouteille en verre de 10 ml - Déclaration de commercialisation non communiquée:;372 132-6 ou 4009 372 132 6 4 - 10 ampoule(s) bouteille en verre de 10 ml - Déclaration de commercialisation non communiquée:;372 133-2 ou 4009 372 133 2 5 - 20 ampoule(s) bouteille en verre de 10 ml - Déclaration de commercialisation non communiquée:;

Autres informations

Statut

  • Source:
  • ANSM - Agence Nationale de Sécurité du Médicament et des Produits de Santé
  • Statut de autorisation:
  • Valide
  • Numéro d'autorisation:
  • 62755917
  • Date de l'autorisation:
  • 14-06-1995
  • Dernière mise à jour:
  • 09-08-2017

Notice: composition, indications thérapeutiques, interactions, posologie, effets indésirable, grossesse, allaitement

NOTICE

ANSM-Misàjourle:14/12/2010

Dénominationdumédicament

GLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableenampoule

Encadré

Veuillezlireattentivementcettenoticeavantd'utilisercemédicament.Ellecontientdes

informationsimportantespourvotretraitement.

Sivousavezd'autresquestions,sivousavezundoute,demandezplusd'informationsàvotre

médecinouàvotrepharmacien.

Gardezcettenotice,vouspourriezavoirbesoindelarelire.

Sivousavezbesoindeplusd'informationsetdeconseils,adressez-vousàvotrepharmacien.

Silessymptômess'aggraventoupersistent,consultezvotremédecin.

Sivousremarquezdeseffetsindésirablesnonmentionnésdanscettenotice,ousivous

ressentezundeseffetsmentionnéscommeétantgrave,veuillezeninformervotremédecinou

votrepharmacien.

Sommairenotice

Danscettenotice:

1.QU'EST-CEQUEGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableen

ampouleETDANSQUELSCASEST-ILUTILISE?

2.QUELLESSONTLESINFORMATIONSACONNAITREAVANTD'UTILISERGLUCOSE

RENAUDIN30POURCENT(3g/10ml),solutioninjectableenampoule?

3.COMMENTUTILISERGLUCOSERENAUDIN30POURCENT(3g/10ml),solution

injectableenampoule?

4.QUELSSONTLESEFFETSINDESIRABLESEVENTUELS?

5.COMMENTCONSERVERGLUCOSERENAUDIN30POURCENT(3g/10ml),solution

injectableenampoule?

6.INFORMATIONSSUPPLEMENTAIRES

1.QU'EST-CEQUEGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableen

ampouleETDANSQUELSCASEST-ILUTILISE?

Classepharmacothérapeutique

PRODUITD'APPORTGLUCIDIQUE

(B:sangetorganeshématopoïétiques)

Indicationsthérapeutiques

Apportcaloriqueglucidique.

Alimentationparentérale.

Traitementd'urgencedeshypoglycémiesaiguës.

2.QUELLESSONTLESINFORMATIONSACONNAITREAVANTD'UTILISERGLUCOSE

RENAUDIN30POURCENT(3g/10ml),solutioninjectableenampoule?

Listedesinformationsnécessairesavantlaprisedumédicament

Sansobjet.

Contre-indications

N'utilisezjamaisGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableen

ampoule:encasd'inflationhydrique(rétentiond'eau).

Précautionsd'emploi;misesengardespéciales

FaitesattentionavecGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectable

enampoule:

Misesengardespéciales

Seconformeràunevitessedeperfusionlentedufaitdurisquedevoirapparaîtreunediurèse

osmotiqueindésirable.

Précautionsd'emploi

Surveillerl'étatcliniqueetbiologique,notammentl'équilibrehydro-sodé,lakaliémie,la

phosphorémie,laglycémieetlaglycosurie.

Sinécessaire,supplémenterl'apportparentéraleninsulineetenpotassium.

Chezlediabétique,surveillerlaglycémieetlaglycosurieetajusteréventuellementlaposologie

del'insuline.

Nepasadministrerdusangsimultanémentaumoyendumêmenécessaireàperfusion,àcause

durisquedepseudo-agglutination.

ENCASDEDOUTENEPASHESITERADEMANDERL'AVISDEVOTREMEDECINOUDE

VOTREPHARMACIEN.

Interactionsavecd'autresmédicaments

Priseouutilisationd'autresmédicaments:

Encasd'adjonctiondemédicaments,tenircomptedelaprésenceduglucoseetvérifierla

compatibilitédesmédicamentsajoutésaveclerécipient.

Sivousprenezouavezprisrécemmentunautremédicament,ycomprisunmédicamentobtenu

sansordonnance,parlez-enàvotremédecinouàvotrepharmacien.

Interactionsaveclesalimentsetlesboissons

Sansobjet.

Interactionsaveclesproduitsdephytothérapieouthérapiesalternatives

Sansobjet.

Utilisationpendantlagrossesseetl'allaitement

Grossesseetallaitement

Ceproduitpeutêtreadministrépendantlagrossesseoul'allaitement,sinécessaire.

Demandezconseilàvotremédecinouàvotrepharmacienavantdeprendretoutmédicament.

Sportifs

Sansobjet.

Effetssurl'aptitudeàconduiredesvéhiculesouàutiliserdesmachines

Sansobjet.

Listedesexcipientsàeffetnotoire

Sansobjet.

3.COMMENTUTILISERGLUCOSERENAUDIN30POURCENT(3g/10ml),solution

injectableenampoule?

Instructionspourunbonusage

Sansobjet.

Posologie,Modeet/ouvoie(s)d'administration,Fréquenced'administrationetDuréedu

traitement

Posologie

Enfonctiondel'étatclinique,dupoids,del'âgedumaladeetdesthérapeutiques

complémentaires.

Modeetvoied'administration

Perfusionintraveineuseparvoiepériphérique.

Encasd'adjonctiondemédicaments,tenircomptedelaprésenceduglucoseetvérifierla

compatibilitédesmédicamentsajoutésaveclerécipient.

Fréquenced'administration

Perfusionlentesur24heures.

Duréedutraitement

Alademande.

Symptômesetinstructionsencasdesurdosage

SivousavezutiliséplusdeGLUCOSERENAUDIN30POURCENT(3g/10ml),solution

injectableenampoulequevousn'auriezdû:

Hyperglycémie(tauxanormalementélevédesucredanslesang)etdiurèseosmotique

(augmentationdelaquantitéd'urineémise),letraitementestsymptomatique.

Instructionsencasd'omissiond'uneoudeplusieursdoses

Sansobjet.

Risquedesyndromedesevrage

Sansobjet.

4.QUELSSONTLESEFFETSINDESIRABLESEVENTUELS?

Descriptiondeseffetsindésirables

Commetouslesmédicaments,GLUCOSERENAUDIN30POURCENT(3g/10ml),solution

injectableenampouleestsusceptibled'avoirdeseffetsindésirables,bienquetoutlemonden'y

soitpassujet.

Leseffetspouvantêtrerencontréssontlessuivants:

hyperglycémie

polyurie(émissiond'unequantitéexcessived'urine),

déshydratation

thromboseveineuseprofonde(formationd'uncaillotdesangquiobstrueuneveineprofonde)

Sivousremarquezdeseffetsindésirablesnonmentionnésdanscettenotice,ousicertainseffets

indésirablesdeviennentgraves,veuillezeninformervotremédecinouvotrepharmacien.

5.COMMENTCONSERVERGLUCOSERENAUDIN30POURCENT(3g/10ml),solution

injectableenampoule?

Tenirhorsdelaportéeetdelavuedesenfants.

Datedepéremption

NepasutiliserGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableen

ampouleaprèsladatedepéremptionmentionnéesurleconditionnementextérieur.

Aprèsouverture,leproduitdoitêtreutiliséimmédiatement.

Conditionsdeconservation

Avantouverture:Pasdeprécautionsparticulièresdeconservation.

Sinécessaire,misesengardecontrecertainssignesvisiblesdedétérioration

Vérifierlescompatibilitésavantd'effectuerlesmélanges.

Vérifierlalimpiditéetlacouleuravantusage.

Lesmédicamentsnedoiventpasêtrejetésautoutàl'égoutouaveclesorduresménagères.

Demandezàvotrepharmaciencequ'ilfautfairedesmédicamentsinutilisés.Cesmesures

permettrontdeprotégerl'environnement.

6.INFORMATIONSSUPPLEMENTAIRES

Listecomplètedessubstancesactivesetdesexcipients

QuecontientGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableen

ampoule?

Lasubstanceactiveest:

Glucosemonohydraté..........................................................................................................................3,3

Quantitécorrespondantàglucoseanhydre.............................................................................................

3,0g

Pour10ml.

Osmolarité:1680mOsm/l

L'autrecomposantest:

Eaupourpréparationsinjectables.

Formepharmaceutiqueetcontenu

Qu'est-cequeGLUCOSERENAUDIN30POURCENT(3g/10ml),solutioninjectableen

ampouleetcontenudel'emballageextérieur?

Cemédicamentseprésentesousformedesolutioninjectable.Boîtede5,10,20,30,50ou100

ampoulesde10ml.

Nometadressedutitulairedel'autorisationdemisesurlemarchéetdutitulairedel'autorisation

defabricationresponsabledelalibérationdeslots,sidifférent

Titulaire

LABORATOIRERENAUDIN

ZONEARTISANALEERROBI

ITXASSOU

64250CAMBOLESBAINS

Exploitant

LABORATOIRERENAUDIN

Z.AERROBI

64250ITXASSOU

Fabricant

LABORATOIRERENAUDIN

Z.AERROBI

64250ITXASSOU

NomsdumédicamentdanslesEtatsmembresdel'EspaceEconomiqueEuropéen

Sansobjet.

Dated’approbationdelanotice

Ladernièredateàlaquellecettenoticeaétéapprouvéeestle{date}.

AMMsouscirconstancesexceptionnelles

Sansobjet.

InformationsInternet

DesinformationsdétailléessurcemédicamentsontdisponiblessurlesiteInternetdel’Afssaps

(France).

Informationsréservéesauxprofessionnelsdesanté

Sansobjet.

Autres

Sansobjet.

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Botanicals and preparations derived from these are among the substances frequently added to foods and food supplements, yet the safety of many botanicals has not been systematically assessed. In the context of the EU‐FORA fellowship programme, the fellow performed an assessment on the safety of the botanical Gymnema sylvestre, in accordance with EFSA's guidance on the assessment of safety of botanicals. Although preparations of G. sylvestre are marketed as f...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

Requiring a new warning about this risk to be added to the prescribing information of all SGLT2 inhibitors and to the patient Medication Guide.

FDA - U.S. Food and Drug Administration

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

21-6-2018

FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes

FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes

glucose monitoring system, implantable glucose sensor, adults, diabetes

FDA - U.S. Food and Drug Administration

30-11-2018

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of  blood glucose monitors to empower patients with diabetes with reliable  tools to manage their health. Read more:  https://go.usa.gov/xPMyA   #MedicalDevice

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of blood glucose monitors to empower patients with diabetes with reliable tools to manage their health. Read more: https://go.usa.gov/xPMyA  #MedicalDevice

#FDA In Brief: @US_FDA takes steps to advance the safety and accuracy of blood glucose monitors to empower patients with diabetes with reliable tools to manage their health. Read more: https://go.usa.gov/xPMyA  #MedicalDevice

FDA - U.S. Food and Drug Administration

6-11-2018

November is #DiabetesAwarenessMonth  #DYK using a glucose meter to check and monitor blood sugar is a daily part of life for millions of Americans with diabetes? Check out the @US_FDA's tips on how to safely use glucose meters and test strips for diabetes

November is #DiabetesAwarenessMonth #DYK using a glucose meter to check and monitor blood sugar is a daily part of life for millions of Americans with diabetes? Check out the @US_FDA's tips on how to safely use glucose meters and test strips for diabetes

November is #DiabetesAwarenessMonth #DYK using a glucose meter to check and monitor blood sugar is a daily part of life for millions of Americans with diabetes? Check out the @US_FDA's tips on how to safely use glucose meters and test strips for diabetes: https://go.usa.gov/xPdK4 

FDA - U.S. Food and Drug Administration

22-6-2018

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today.  #cgm #diabetes #fda #medicaldevice  https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5 pic.twitter.com/6zs99z2Dlz

First continuous glucose monitoring system that includes a fully implantable glucose sensor that can be worn up to 90 days approved today. #cgm #diabetes #fda #medicaldevice https://go.usa.gov/xUqg5  pic.twitter.com/6zs99z2Dlz

FDA - U.S. Food and Drug Administration

11-6-2018

.@CMSGov is issuing guidance today to make sure patients who use Continuous Glucose Monitors (CGMs) to help control their #diabetes can use apps on their smartphones in conjunction with CGM receivers. Learn more:  http://go.cms.gov/1jc4cdC 

.@CMSGov is issuing guidance today to make sure patients who use Continuous Glucose Monitors (CGMs) to help control their #diabetes can use apps on their smartphones in conjunction with CGM receivers. Learn more: http://go.cms.gov/1jc4cdC 

. @CMSGov is issuing guidance today to make sure patients who use Continuous Glucose Monitors (CGMs) to help control their #diabetes can use apps on their smartphones in conjunction with CGM receivers. Learn more: http://go.cms.gov/1jc4cdC 

FDA - U.S. Food and Drug Administration